
Solid Biosciences Inc.
- Address
- 500 Rutherford Avenue
Sponsor Overview
Specializations
Duchenne muscular dystrophy
Solid Biosciences Inc. focuses on neuromuscular disease research, with activity centered on Duchenne muscular dystrophy and the development of gene therapy approaches aimed at restoring microdystrophin expression in muscle tissue.
- Muscle biopsy biomarker assessment
- Microdystrophin expression
- Intravenous gene delivery
The sponsor’s clinical research interest is concentrated on treatment strategies for the genetic basis of Duchenne muscular dystrophy, with emphasis on skeletal muscle function and disease-related protein restoration.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 1/2 Multicenter Open-Label Study on Safety and Efficacy of SGT-003 Gene Therapy in Ambulant Males with Duchenne Muscular Dystrophy | Italy | Recruiting |
| Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Single Intravenous SGT‑003 Gene Therapy in Ambulant Male Patients with Duchenne Muscular Dystrophy | Belgium France Germany Italy Spain The Netherlands | Not Yet Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 13 sites across their trial portfolio.
Therapeutic Focus
- 1.Musculoskeletal Diseases2 trials238 other sponsors
Partnered Research Centres
13 centres- Address
- Piazza Dell'ospedale Maggiore 3, 20162 Milan
- Address
- Largo Francesco Vito 1, 00168 Rome
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- Passeig De Sant Joan De Deu 2, 08950 Esplugues de Llobregat
- Address
- Avenida Fernando Abril Martorell 106, 46026 Valencia
- Address
- Passeig De La Vall D'Hebron 119-129, 08035 Barcelona
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Solid Biosciences Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.






